Welcome to The Visible Embryo

Home-- -History-- -Bibliography- -Pregnancy Timeline- --Prescription Drugs in Pregnancy- -- Pregnancy Calculator- --Female Reproductive System- -Contact
 

Welcome to The Visible Embryo, a comprehensive educational resource on human development from conception to birth.

The Visible Embryo provides visual references for changes in fetal development throughout pregnancy and can be navigated via fetal development or maternal changes.

The National Institutes of Child Health and Human Development awarded Phase I and Phase II Small Business Innovative Research Grants to develop The Visible Embryo. Initally designed to evaluate the internet as a teaching tool for first year medical students, The Visible Embryo is linked to over 600 educational institutions and is viewed by more than one million visitors each month.

Today, The Visible Embryo is linked to over 600 educational institutions and is viewed by more than 1 million visitors each month. The field of early embryology has grown to include the identification of the stem cell as not only critical to organogenesis in the embryo, but equally critical to organ function and repair in the adult human. The identification and understanding of genetic malfunction, inflammatory responses, and the progression in chronic disease, begins with a grounding in primary cellular and systemic functions manifested in the study of the early embryo.

WHO International Clinical Trials Registry Platform


The World Health Organization (WHO) has created a new Web site to help researchers, doctors and
patients obtain reliable information on high-quality clinical trials. Now you can go to one website and search all registers to identify clinical trial research underway around the world!



Home

History

Bibliography

Pregnancy Timeline

Prescription Drug Effects on Pregnancy

Pregnancy Calculator

Female Reproductive System

Contact The Visible Embryo

News Alerts Archive

Disclaimer: The Visible Embryo web site is provided for your general information only. The information contained on this site should not be treated as a substitute for medical, legal or other professional advice. Neither is The Visible Embryo responsible or liable for the contents of any websites of third parties which are listed on this site.
Content protected under a Creative Commons License.

No dirivative works may be made or used for commercial purposes.

Return To Top Of Page
Pregnancy Timeline by SemestersFetal liver is producing blood cellsHead may position into pelvisBrain convolutions beginFull TermWhite fat begins to be madeWhite fat begins to be madeHead may position into pelvisImmune system beginningImmune system beginningPeriod of rapid brain growthBrain convolutions beginLungs begin to produce surfactantSensory brain waves begin to activateSensory brain waves begin to activateInner Ear Bones HardenBone marrow starts making blood cellsBone marrow starts making blood cellsBrown fat surrounds lymphatic systemFetal sexual organs visibleFinger and toe prints appearFinger and toe prints appearHeartbeat can be detectedHeartbeat can be detectedBasic Brain Structure in PlaceThe Appearance of SomitesFirst Detectable Brain WavesA Four Chambered HeartBeginning Cerebral HemispheresFemale Reproductive SystemEnd of Embryonic PeriodEnd of Embryonic PeriodFirst Thin Layer of Skin AppearsThird TrimesterSecond TrimesterFirst TrimesterFertilizationDevelopmental Timeline
CLICK ON weeks 0 - 40 and follow along every 2 weeks of fetal development
Google Research artcles published since 2007
 
 

Home | Pregnancy Timeline | News Alerts | News Archive May 31, 2013

 


Above: Yeast Cells


Using yeast cells as a model system, researchers found a specific factor
in the cell, abbreviated as Cue1, not only acts as a receptor and activator
in the degrading of damaged proteins, but also marks a defective
protein with a molecular tag.





WHO Child Growth Charts

 

 

 

New insights into protein function within the cell

Cells have a sophisticated system to control and dispose of defective, superfluous proteins in order to prevent damage to the body—and now a newly discovered enzyme function has also been added as vital to this process.

Using yeast cells as a model organism, researchers show that a specific factor in the cell, abbreviated as Cue1, is not only a receptor and activator for a component of the degradation apparatus, but also marks a defective protein with a molecular tag identifying it for degradation. The work is published in the journal Molecular Cell.


Proteins are molecular machines in the cells of an organism.

Different types of proteins perform many different functions: They transport materials to their destination, ward off pathogens, enable chemical reactions in the cell and much more. Many proteins are produced in a cell organelle, the endoplasmic reticulum (ER), are then folded into specific shapes and finally transported to their destination.

Some proteins are only required for a specific, time-limited purpose and must be degraded (taken apart to be reused) once their purpose has been served. But errors also frequently occur during production and folding. These defective proteins are not functional and can even harm an organism. Therefore they, too, must be degraded.


The cells therefore have a sophisticated system to dispose of defective, superfluous proteins. In the ER (endoplasmic reticulum) there is a special process for protein degradation, known as ER-associated degradation (ERAD).

This system contains a number of enzymes that cooperate to ensure that a defective protein is marked with a molecular tag, the molecule ubiquitin—a process known as ubiquitylation.

A chain of four to six molecules serves as the degradation signal. A protein tagged with such a molecular chain is transported to the proteasome, the protein-cleaving machinery of the cell, where it is separated into its components.

This ubiquitin-proteasome system is found in all eukaryotic cells; it is ubiquitous (everywhere). It is one of the most complex cellular systems and protects the body from severe diseases. Defective proteins that escape this system trigger serious diseases such as Alzheimer's, Parkinson's, Huntington's disease, cystic fibrosis or diabetes.

The scientist who discovered this protective program is Professor Ciechanover. He received the Nobel Prize in Chemistry in 2004 for this achievement together with Professor Avram Hershko (Technion) and Professor Irwin Rose (University of California, Irvine, USA).


Several enzymes must work in concert to facilitate the attachment of a ubiquitin chain to a defective protein.

Some of these enzymes are anchored in the membrane of the ER, others such as the enzyme Ubc7 swim freely inside the cell.

A factor called CUE1, which itself is bound to the membrane, is responsible for recruiting Ubc7 and escorting it to the enzymes at the membrane. To achieve this, it has a domain which binds specifically to Ubc7. Another domain of the factor is the so-called CUE domain.

Drs. Bagola and Professor Sommer have studied its function in yeast cells together with their colleagues Professor Glickman and Professor Ciechanover.


The CUE domain is a ubiquitin-binding domain (UBD). UBDs bind to specific ubiquitin patterns. For example, they can recognize whether one or more ubiquitin molecules have been attached to a protein and how the respective ubiquitin molecules are linked together in chains. The ubiquitin pattern determines which ubiquitin domain binds to which protein and thus determines the subsequent fate of the protein.

The MDC and Technion researchers, who have collaborated closely for many years, showed that the CUE domain of the factor Cue1 binds to ubiquitin chains that are linked together via a specific building block of the individual ubiquitin molecules. These chains subsequently serve as a degradation signal for proteins. In addition, the researchers found that the CUE domain also has a direct impact on the length of the ubiquitin chains: If the CUE domain was lacking or limited in its function due to a mutation, the ubiquitin chains developed more slowly and were shorter in length. Apparently, the CUE domain stabilizes the ubiquitin chains, allowing additional ubiquitin molecules to be attached more easily.

In yeast cells, the researchers found that the CUE domain of Cue1 actually affects how well the ERAD system can degrade proteins. The researchers suspect that the CUE domain is used specifically for the disposal of proteins which are bound to the ER membrane. However, they seem to have no influence on the degradation of soluble proteins. "Our results show that a ubiquitin-binding domain can also regulate the formation of ubiquitin chains," the researchers said. "This function was previously unknown until now."

* Ubiquitin binding by a CUE domain regulates ubiquitin chain formation by ERAD E3 ligases.

Other members of this team: Dr. Katrin Bagola and Professor Thomas Sommer of the Max Delbrück Center for Molecular Medicine (MDC) Berlin-Buch as well as Professor Michael Glickman and Professor Aaron Ciechanover of Technion, the Technical University of Israel in Haifa.

Katrin Bagola1, Maximilian von Delbrück1, Gunnar Dittmar1, Martin Scheffner3, Inbal Ziv4, Michael H. Glickman4, Aaron Ciechanover5, and Thomas Sommer1, 2

1Max-Delbrück-Center for Molecular Medicine, Robert-Rössle-Strasse 10, D-13122 Berlin, Germany

2Humboldt-University zu Berlin, Institute for Biology, Invalidenstr.43, D-10115 Berlin, Germany

3Department of Biology, Konstanz Research School Chemical Biology, University of Konstanz, Konstanz, Germany

4Department of Biology and 5Cancer and Vascular Biology Research Center, The Rappaport Faculty of Medicine and Polak Cancer Center, Technion-Israel Institute of Technology, Haifa 31096, Israel

Original article: https://www.mdc-berlin.de/41041085/en/news/2013/20130528-german_and_israeli_scientists_gain_new_ins